Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OCX-909
- Development stage
- Preclinical
- Lead developer
- Ocean Biomedical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
OCX-909 is a bispecific antibody targeting both chitinase 3-like 1 (CHI3L1, also known as YKL-40) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), under development by Ocean Biomedical for the treatment of glioblastoma multiforme (GBM) and other cancer indications. It functions as an immunotherapy by combining immune checkpoint inhibition (via CTLA-4) with modulation of the tumor microenvironment (via CHI3L1 inhibition), aiming to enhance immune-mediated antitumor effects. The molecule employs mechanisms such as antibody-dependent cellular cytotoxicity, checkpoint inhibition, and T lymphocyte stimulation. Development is currently preclinical for GBM and in research for other cancers. The drug originated from Brown University and is being developed by Ocean Biomedical[1][3][5].
- Other names
- Anti-Chi3l1/CTLA-4 bispecific antibody
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CHI3L1 (Chitinase-3-like protein 1)
Beyond the preview
Go deeper on OCX-909.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OCX-909.